Decernotinib (VX-509,adelatinib) chemical structure
Chemical structureResearch use only
CAT. NO. DC8171Featured

Decernotinib (VX-509,adelatinib)

Pack Sizes & Prices

TotalUS$550
We match the best price and quality on market.
Product overview

Description & Application

Decernotinib is a potent, orally active JAK3 inhibitor, with Kis of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.

ParameterValue
Chemical NameDecernotinib
CAS No.944842-54-0
SynonymsVX-509;decernotinib;(2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide;VRT-831509;(2R)-2-Methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)butanamide;VRT 831509;VX 509;Adelatinib;MZK2GP0RHK;AK170453;(2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide;(R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide;VX509;Decernotinib [USAN:INN];Decernotinib (USAN/INN)
FormulaC18H19F3N6O
M.Wt392.3783
SMILESFC(C([H])([H])N([H])C([C@@](C([H])([H])[H])(C([H])([H])C([H])([H])[H])N([H])C1C([H])=C([H])N=C(C2=C([H])N([H])C3=C2C([H])=C([H])C([H])=N3)N=1)=O)(F)F
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Decernotinib is a potent, orally active JAK3 inhibitor, with Kis of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.

In Vitro

Decernotinib (VX-509) is a potent JAK3 inhibitor, with Kis of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively. Decernotinib potently blocks T-cell proliferation with a mean IC50 of 170 ± 101 nM, and inhibits IL-2-stimulated T-cell proliferation (IC50, 140 and 400 nM). VX-509 is also cytotoxic to B-cell in response to CD40L and IL-4 (IC50, 50 nM)[1].

In Vivo

Decernotinib (VX-509, 10, 25, or 50 mg/kg, p.o.) significantly and dose-dependently inhibits the increases in ankle diameter and paw weight occuring in response to collagen injections in rats. Decernotinib potently alleviates cartilage damage and bone resorption in rats. Decernotinib (10, 25, or 50 mg/kg, p.o., b.i.d.) suppresses ear edema in a mouse model of delayed-type hypersensitivity[1].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Product documentation

View online datasheetRequest COA / MSDS

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Solution calculator

Related research products

AZD1480 chemical structureDC5032

AZD1480

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. IC50 value: 0.26 nM Target: JAK2 in vitro: AZD1480 demonstrated…

View activity & prices
BMS-911543 chemical structureDC4175

BMS-911543

BMS-911543 is a selective JAK2 inhibitor, with IC50s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC50, 75, 360, 66 nM, respectively).

View activity & prices
JAK2 Inhibitor V,Z3 chemical structureDC7436

JAK2 Inhibitor V,Z3

JAK2 Inhibitor V, Z3 is a cell-permeable pyridinylbutanone compound that inhibits both JAK2 and the active V167F mutant cellular autophosphorylation. JAK2 Inhibitor V, Z3 displays no effect against cellular Tyk 2…

View activity & prices
TG101209 chemical structureDC7317

TG101209

TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

View activity & prices

Cart

Request quotation